key: cord-0298689-z42enwk6
authors: Meewan, Ittipat; Kattoula, Jacob; Kattoula, Julius Y.; Skinner, Danielle; Fajtová, Pavla; Giardini, Miriam A.; Woodworth, Brendon; McKerrow, James H.; de Siqueira-Neto, Jair Lage; O’Donoghue, Anthony J.; Abagyan, Ruben
title: Discovery of Potent Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L
date: 2021-10-20
journal: bioRxiv
DOI: 10.1101/2021.10.19.465036
sha: 3cddc92cb54eec56c17050676434b215c105d28b
doc_id: 298689
cord_uid: z42enwk6

There are currently no FDA approved inhibitors of SARS-CoV-2 viral proteases with specific treatment for post-exposure of SARS-CoV-2. Here, we discovered inhibitors containing thiuram disulfide or dithiobis-(thioformate) tested against three key proteases in SARS CoV-2 replication including SARS CoV-2 Main Protease (Mpro), SARS CoV-2 Papain Like Protease (PLpro), and human cathepsin L. The use of thiuram disulfide and dithiobis-(thioformate) covalent inhibitor warheads was inspired by disulfiram, a currently prescribed drug commonly used to treat chronic alcoholism that at the present time is in Phase 2 clinical trials against SARS-CoV-2. At the maximal allowed dose, disulfiram is associated with adverse effects. Our goal was to find more potent inhibitors that target both viral proteases and one essential human protease to reduce the dosage and minimize the adverse effects associated with these agents. We found that compounds coded as RI175, JX 06, and RI172 are the most potent inhibitors from an enzymatic assay against SARS-CoV-2 Mpro, SARS-CoV-2 PLpro, and human cathepsin L with IC50s of 330, 250 nM, and 190 nM about 4.5, 17, and 11.5-fold more potent than disulfiram, respectively. The identified protease inhibitors in this series were also tested against SARS CoV-2 in a cell-based and toxicity assay and were shown to have similar or greater antiviral effect than disulfiram. The identified triple protease inhibitors and their derivatives are promising candidates for treatment of the Covid-19 virus and related variants.

SARS-CoV-2 PLpro (24.46 nM final concentration) enzymatic assays were performed in reaction 148 buffer containing 50 mM HEPES pH 6.5, 150 mM NaCl and 0.01% Tween 20 using 50 µM of Z-149 RLRGG-AMC fluorogenic substrate. The positive control for these assays was 10 µM Ebselen. 150 Human thrombin (678.3 nM final concentration) enzymatic assays were carried out in 50 mM Tris, 151 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35, pH 7.5 using 100 µM Boc-VPR-AMC as the of cysteine active residues of Mpro and PLpro becoming their oxidized cysteine form (Fig 3) .

Since cathepsin L contains cysteine as an active residue similar to Mpro and PLpro(34,35), we 232 tested whether these compounds could also target cathepsin L, perhaps providing small molecules 233 that target multiple key proteins for the viral replication process, producing a more favorable 

All References

SARS-CoV-2 and the Ongoing Clinical Trials

Disulfiram for COVID-19 (DISCO) Trial (DISCO)